SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:gu ;lar1:(lu)"

Sökning: LAR1:gu > Lunds universitet

  • Resultat 1-10 av 3329
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
3.
  • Aasa, Anna, et al. (författare)
  • Collecting dialect data and making use of them an interim report from Swedia 2000
  • 2000
  • Ingår i: Proceedings FONETIK 2000. - University of Gothenburg. ; s. 17-20
  • Konferensbidrag (övrigt vetenskapligt)abstract
    • This paper consists of two, somewhat disparate parts. In the first part, some experiences of two years of fieldwork are summarized, concentrating, as the subtitle suggests, on the very heart of phonetic fieldwork: the encounters and interviews with the informants. As a result of the fieldwork, the project now has access to recordings from approximately 1300 speakers of more than 100 dialects of Swedish. We are currently initiating research on various aspects of the sound patterns of these dialects. The second part of the paper is meant to give an overview of some of our research plans for the near future.
4.
  • Abdelnour, C, et al. (författare)
  • Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia
  • 2016
  • Ingår i: Movement Disorders. - John Wiley & Sons. - 0885-3185. ; 31:8, s. 1203-1208
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Alzheimer's disease pathologies are common in dementia with Lewy bodies, but their clinical relevance is not clear. CSF biomarkers amyloid beta 1-42, total tau, and tau phosphorylated at threonine 181 reflect Alzheimer's disease neuropathology antemortem. In PD, low CSF amyloid beta 1-42 predict long-term cognitive decline, but little is known about these biomarkers as predictors for cognitive decline in Lewy body dementia. The aim of this study was to assess whether Alzheimer's disease CSF biomarkers predict cognitive decline in Lewy body dementia. Methods: From a large European dementia with Lewy bodies multicenter study, we analyzed baseline Alzheimer's disease CSF biomarkers and serial MMSE (baseline and 1- and 2-year follow-up) in 100 patients with Lewy body dementia. Linear mixed-effects analyses, adjusted for sex, age, baseline MMSE, and education, were performed to model the association between CSF biomarkers and rate of cognitive decline measured with MMSE. An Alzheimer's disease CSF profile was defined as pathological amyloid beta 1-42 plus pathological total tau or phosphorylated tau. Results: The Alzheimer's disease CSF profile, and pathological levels of amyloid beta 1-42, were associated with a more rapid decline in MMSE (2.2 [P < 0.05] and 2.9 points difference [P < 0.01], respectively). Higher total tau values showed a trend toward association without statistical significance (2.0 points difference; P = 0.064), whereas phosphorylated tau was not associated with decline. Conclusions: Reduced levels of CSF amyloid beta 1-42 were associated with more rapid cognitive decline in Lewy body dementia patients. Future prospective studies should include larger samples, centralized CSF analyses, longer follow-up, and biomarker-pathology correlation. © 2016 International Parkinson and Movement Disorder Society.
  •  
5.
  • Abendstein, Helmut, et al. (författare)
  • Quality of Life and Head and Neck Cancer: A 5 Year Prospective Study.
  • 2005
  • Ingår i: Laryngoscope. - Lippincott Williams & Wilkins. - 1531-4995. ; 115:12, s. 2183-2192
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: Assessment of health-related quality of life (HRQL) in head and neck cancer patients from diagnosis to 5 years after start of treatment. STUDY DESIGN: A prospective, descriptive study METHODS: three hundred fifty-seven patients from Norway and Sweden filled in HRQL questionnaires, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and the EORTC QLQ-H and N35, six times during the first year and then after 5 years. At 5 years, 167 (87%) of the 192 living patients filled in questionnaires. RESULTS: Group data: clinical significant improvements in HRQL were not found between 1 and 5 years. Problems with teeth, opening of the mouth, dryness in the mouth, and sticky saliva were persistent or worsening. Similar findings were found regardless of sex, age, stage, or site when clinical significant changes are considered. Patients who died between 1 and 5 years reported reduced HRQL on 15 of 28 scales at 1 year compared with the survivors. Individual data: 40% of patients reported improved global HRQL from diagnosis to 5 years after start of treatment. In addition, 11% had "top scores" at both assessment points. The pattern in global HRQL scores also applies for most of the other function and symptom scales. CONCLUSION: After the first year after treatment, recovery of the persisting side effects of treatment cannot be expected for the group as a whole. Patients must be prepared for this. Some individual patients experience improvement in global HRQL. HRQL assessments in daily clinical practice can identify patients who are in need of additional support and symptom relief.
  •  
6.
  • Aboul-Ata, Aboul-Ata E, et al. (författare)
  • Plant-Based Vaccines: Novel and Low-Cost Possible Route for Mediterranean Innovative Vaccination Strategies
  • 2014
  • Ingår i: Advances in Virus Research. - San Diego : Elsevier Academic Press Inc. - 0065-3527. ; 89, s. 1-37
  • Forskningsöversikt (refereegranskat)abstract
    • A plant bioreactor has enormous capability as a system that supports many biological activities, that is, production of plant bodies, virus-like particles (VLPs), and vaccines. Foreign gene expression is an efficient mechanism for getting protein vaccines against different human viral and nonviral diseases. Plants make it easy to deal with safe, inexpensive, and provide trouble-free storage. The broad spectrum of safe gene promoters is being used to avoid risk assessments. Engineered virus-based vectors have no side effect. The process can be manipulated as follows: (a) retrieve and select gene encoding, use an antigenic protein from GenBank and/or from a viral-genome sequence, (b) design and construct hybrid-virus vectors (viral vector with a gene of interest) eventually flanked by plant-specific genetic regulatory elements for constitutive expression for obtaining chimeric virus, (c) gene transformation and/or transfection, for transient expression, into a plant-host model, that is, tobacco, to get protocols processed positively, and then moving into edible host plants, (d) confirmation of protein expression by bioassay, PCR-associated tests (RT-PCR), Northern and Western blotting analysis, and serological assay (ELISA), (e) expression for adjuvant recombinant protein seeking better antigenicity, (f) extraction and purification of expressed protein for identification and dosing, (g) antigenicity capability evaluated using parental or oral delivery in animal models (mice and/or rabbit immunization), and (h) growing of construct-treated edible crops in protective green houses. Some successful cases of heterologous gene-expressed protein, as edible vaccine, are being discussed, that is, hepatitis C virus (HCV). R9 mimotope, also named hypervariable region 1 (HVR1), was derived from the HVR1 of HCV. It was used as a potential neutralizing epitope of HCV. The mimotope was expressed using cucumber mosaic virus coat protein (CP), alfalfa mosaic virus CP P3/RNA3, and tobacco mosaic virus (TMV) CP-tobacco mild green mosaic virus (TMGMV) CP as expression vectors into tobacco plants. Expressed recombinant protein has not only been confirmed as a therapeutic but also as a diagnostic tool. Herpes simplex virus 2 (HSV-2), HSV-2 gD, and HSV-2 VP16 subunits were transfected into tobacco plants, using TMV CP-TMGMV CP expression vectors.
  •  
7.
  • Abraham-Nordling, Mirna, et al. (författare)
  • Incidence of hyperthyroidism in Sweden
  • 2011
  • Ingår i: European Journal of Endocrinology. - Society of the European Journal of Endocrinology. - 1479-683X. ; 165:6, s. 899-905
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: The incidence of hyperthyroidism has been reported in various countries to be 23-93/100000 inhabitants per year. This extended study has evaluated the incidence for similar to 40% of the Swedish population of 9 million inhabitants. Sweden is considered to be iodine sufficient country. Methods:All patients including children, who were newly diagnosed with overt hyperthyroidism in the years 2003-2005, were prospectively registered in a multicenter study. The inclusion criteria are as follows:clinical symptoms and/or signs of hyperthyroidism with plasma TSH concentration below 0.2 mIE/l and increased plasma levels of free/total triiodothyronine and/or free/total thyroxine. Patients with relapse of hyperthyroidism or thyroiditis were not included. The diagnosis of Graves' disease (GD), toxic multinodular goiter (TMNG) and solitary toxic adenoma (STA), smoking, initial treatment, occurrence of thyroid-associated eye symptoms/signs, and demographic data were registered. Results:A total of 2916 patients were diagnosed with de novo hyperthyroidism showing the total incidence of 27.6/100 000 inhabitants per year. The incidence of GD was 21.0/100 000 and toxic nodular goiter (TNG=STA+TMNG) occurred in 692 patients, corresponding to an annual incidence of 6.5/100 000. The incidence was higher in women compared with men (4.2:1). Seventy-five percent of the patients were diagnosed with GD, in whom thyroid-associated eye symptoms/signs occurred during diagnosis in every fifth patient. Geographical differences were observed. Conclusion:The incidence of hyperthyroidism in Sweden is in a lower range compared with international reports. Seventy-five percent of patients with hyperthyroidism had GD and 20% of them had thyroid-associated eye symptoms/signs during diagnosis. The observed geographical differences require further studies.
  •  
8.
  • Abraham-Nordling, M, et al. (författare)
  • Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine.
  • 2010
  • Ingår i: European journal of endocrinology / European Federation of Endocrine Societies. - 1479-683X. ; 163:4, s. 651-7
  • Tidskriftsartikel (refereegranskat)abstract
    • Objective: The objective of this study was to investigate quality of life (QoL) in patients with Graves' disease treated with radioiodine or antithyroid drugs. Design and methods: The design of the study consists of an open, prospective, randomized multicenter trial between radioiodine and medical treatment. A total of 308 patients were included in the study group: 145 patients in the medical group and 163 patients in the radioiodine group. QoL was measured with a 36-item Short Form Health Status Survey questionnaire (SF-36) at six time points during the 48-month study period. Results: Patient who developed or got worse of thyroid-associated ophthalmopathy (TAO) at any time point during the 4-year study period (TAO group) had lower QoL when no respect was paid to the mode of treatment. TAO occurred in 75 patients who had radioiodine treatment at some time point during the study period as compared with TAO in 40 medically treated patients (P<0.0009). Comparisons between the group of patients who have had TAO versus the group without TAO, in relation to treatments and time, showed significantly decreased QoL scores for the TAO groups at several time points during the study. In patients without TAO, there were no differences in QoL related to mode of treatment. Conclusions: The QoL in patients with Graves' ophthalmopathy was similar in radioiodine and medically treated patients, but patients who developed or had worsening of TAO had decreased QoL independent of mode of treatment. Furthermore, patients with TAO recovered physically within 1 year but it took twice as long for them to recover mentally.
  •  
9.
  • Abrahamsson, J, et al. (författare)
  • Improved outcome after relapse in children with acute myeloid leukaemia.
  • 2007
  • Ingår i: British journal of haematology. - 0007-1048. ; 136:2, s. 229-236
  • Tidskriftsartikel (refereegranskat)abstract
    • In the Nordic Society for Paediatric Haematology and Oncology paediatric study acute myeloid leukaemia (AML) 93, event-free survival was 50% and overall survival was 66%, indicating that many patients were cured following relapse. Factors influencing outcome in children with relapsed AML were investigated. The study included all 146 children in the Nordic countries diagnosed with AML between 1988 and 2003, who relapsed. Data on disease characteristics and relapse treatment were related to outcome. Sixty-six percentage achieved remission with survival after relapse (5 years) 34 +/- 4%. Of 122 patients who received re-induction therapy, 77% entered remission with 40 +/- 5% survival. Remission rates were similar for different re-induction regimens but fludarabine, cytarabine, granulocyte colony-stimulating factor-based therapy had low treatment-related mortality. Prognostic factors for survival were duration of first complete remission (CR1) and stem cell transplantation (SCT) in CR1. In early relapse (&lt;1 year in CR1), survival was 21 +/- 5% compared with 48 +/- 6% in late relapse. For children receiving re-induction therapy, survival in early relapse was 29 +/- 6% and 51 +/- 6% in late. Patients treated in CR1 with SCT, autologous SCT or chemotherapy had a survival of 18 +/- 9, 5 +/- 5 and 41 +/- 5%, respectively. Survival was 62 +/- 6% in 64 children given SCT as part of their relapse therapy. A significant proportion of children with relapsed AML can be cured, even those with early relapse. Children who receive re-induction therapy, enter remission and proceed to SCT can achieve a cure rate of 60%.
  •  
10.
  • Abrahamsson, Jonas, et al. (författare)
  • Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate.
  • 2011
  • Ingår i: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 1527-7755. ; 29:3, s. 310-5
  • Tidskriftsartikel (refereegranskat)abstract
    • PurposeTo evaluate the early treatment response in children with acute myeloid leukemia (AML) using a response-guided induction strategy that includes idarubicin in the first course.Patients and MethodsAll Nordic children with AML younger than 15 years (n = 151) were treated on the Nordic Society for Pediatric Hematology and Oncology (NOPHO) AML 2004 protocol. After the first course of idarubicin, cytarabine, etoposide, and 6-thioguanin, patients with good response were allowed hematologic recovery before the second course, whereas patients with a poor (&gt;= 15% blasts) or intermediate (5% to 14.9% blasts) were recommended to proceed immediately with therapy. Patients not in remission after the second course received fludarabine, cytarabine, and granulocyte colony-stimulating factor. Poor responders received allogeneic stem-cell transplantation (SCT) as consolidation.ResultsSeventy-four percent of patients had good response, 17% had intermediate response, and 7% had poor response after the first course. The overall remission frequency was 97.4%, with 92% in remission after the second course. The rate of induction death was 1.3%. Patients with an intermediate response had a lower event-free survival of 35% compared with good (61%) and poor responders (82%).ConclusionThe NOPHO-AML 2004 induction strategy gives an excellent remission rate with low toxic mortality in an unselected population. Outcome is worse in patients with intermediate response but may be improved by intensifying consolidation in this group using SCT.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 3329
Åtkomst
fritt online (997)
Typ av publikation
tidskriftsartikel (2989)
konferensbidrag (95)
rapport (67)
bokkapitel (48)
bok (36)
samlingsverk (redaktörskap) (31)
visa fler...
doktorsavhandling (28)
forskningsöversikt (20)
recension (15)
visa färre...
Typ av innehåll
refereegranskat (3008)
övrigt vetenskapligt (294)
populärvet., debatt m.m. (27)
Författare/redaktör
Ohlsson, Claes (91)
Blennow, Kaj (88)
Råstam, Maria, (86)
Anckarsäter, Henrik, (85)
Zetterberg, Henrik (81)
Hansson, Oskar (72)
visa fler...
Minthon, Lennart, (67)
Ljunggren, Östen, (65)
Mellström, Dan (63)
Gillberg, Christophe ... (62)
Blennow, K (51)
Lorentzon, Mattias, (47)
Mellstrom, Dan (46)
Zetterberg, H (44)
Karlsson, Magnus K (44)
Ljunggren, Osten (42)
Lindblad, Ulf, (38)
Olsson, Mats (37)
Vandenput, Liesbeth (36)
Corvellec, Hervé (36)
Minthon, L (34)
Hofman, Albert, (34)
Pendrill, Ann-Marie (34)
Mellström, Dan, 1945 ... (33)
Uller, Tobias, (33)
Karlsson, Magnus, (32)
Ohlsson, C (31)
Källén, Karin, (31)
Lilja, Hans, (30)
Melander, Olle, (30)
Allwood, Carl Martin ... (30)
Wentz, Elisabet, (30)
Mellstrom, D. (30)
Anckarsater, H (28)
Barregard, Lars (27)
Linderholm, Hans (27)
Sterner, Thomas (26)
Londos, Elisabet, (26)
Hugosson, Jonas (24)
Barregård, Lars, 194 ... (24)
Rivadeneira, Fernand ... (24)
Harris, Tamara B. (24)
Dahlin-Ivanoff, Synn ... (24)
Oden, A (23)
Gudnason, Vilmundur, (23)
Engström, Gunnar, (23)
Cederholm, Jan, (23)
Svensson, Johan, (23)
Mattsson, Niklas, (23)
Leboyer, Marion, (23)
visa färre...
Lärosäte
Göteborgs universitet (3329)
Karolinska Institutet (614)
Uppsala universitet (413)
Umeå universitet (292)
Linköpings universitet (232)
visa fler...
Chalmers tekniska högskola (199)
Högskolan i Borås (59)
Stockholms universitet (57)
Sveriges Lantbruksuniversitet (56)
Högskolan i Halmstad (54)
Örebro universitet (45)
Linnéuniversitetet (44)
Kungliga Tekniska Högskolan (38)
Malmö högskola (30)
Högskolan i Jönköping (22)
Högskolan Kristianstad (21)
Karlstads universitet (15)
Högskolan Dalarna (14)
Mittuniversitetet (14)
Högskolan i Skövde (14)
Ersta Sköndal Bräcke högskola (10)
Luleå tekniska universitet (10)
Högskolan Väst (7)
Mälardalens högskola (6)
Högskolan i Gävle (6)
Sophiahemmet Högskola (6)
RISE (5)
Södertörns högskola (3)
VTI - Statens väg- och transportforskningsinstitut (2)
Blekinge Tekniska Högskola (1)
visa färre...
Språk
Engelska (3133)
Svenska (172)
Odefinierat språk (15)
Tyska (5)
Danska (2)
Franska (1)
visa fler...
Spanska (1)
visa färre...
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (2137)
Naturvetenskap (870)
Samhällsvetenskap (636)
Humaniora (180)
Teknik (121)
Lantbruksvetenskap (78)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy